Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.

Cancer science - 1 Nov 2021

Takai Erina, Omata Wataru, Totoki Yasushi, Nakamura Hiromi, Shiba Satoshi, Takahashi Akira, Namikawa Kenjiro, Mori Taisuke, Yamazaki Naoya, Shibata Tatsuhiro, Yachida Shinichi

Abstract excerpt

Assessment of treatment efficacy of immune checkpoint inhibitors in melanoma patients is difficult as the response to these therapies varies among patients or lesions. The clonal evolution of cancer during immune checkpoint blockade therapy could cause treatment resistance. We investigated the potential of liquid biopsy in monitoring the mutational profiles of metastatic melanoma during immunotherapy. Plasma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Circulating Tumor DNA
Share to Exome Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Liquid Biopsy

Share to Longitudinal Studies

Share to Melanoma

Share to Skin Neoplasms

Share to Tumor Burden

Source

Open in PubMed Open full text

Identifiers

PMID: 34477284
DOI: 10.1111/cas.15088
PMCID: PMC8586661

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.PMID 34477284Read ↗

Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.Semantic proximity Read ↗

Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma.Semantic proximity Read ↗

Circulating Tumor DNA (ctDNA) Clearance After Immune Checkpoint Inhibition (ICI) with Radiotherapy (RT) as a Prognostic Biomarker for Advanced MelanomaSemantic proximity Read ↗

In-depth assessment of BRAF, NRAS, KRAS, EGFR, and PIK3CA mutations on cell-free DNA in the blood of melanoma patients receiving immune checkpoint inhibitionSemantic proximity Read ↗

Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma.Semantic proximity Read ↗

Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment.Semantic proximity Read ↗

Methylation Markers in Cutaneous Melanoma: Unravelling the Potential Utility of Their Tracking by Liquid BiopsySemantic proximity Read ↗

Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients.Semantic proximity Read ↗

Individualized circulating tumor DNA monitoring in two dogs with malignant melanoma.Semantic proximity Read ↗

Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic MelanomaSemantic proximity Read ↗

Liquid Biopsy in Melanoma: Significance in Diagnostics, Prediction and Treatment Monitoring.Semantic proximity Read ↗

Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for Diagnosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.